To determine the overall survival and @entity344 for @entity1 treated with salvage definitive chemo-radiotherapy after primary surgery for locoregional relapse of @entity189 . A retrospective review of 525 @entity1 who had a resection for oesophageal or oesophagogastric @entity189 at Princess Alexandra Hospital identified 14 @entity1 treated with salvage definitive radiotherapy or chemo-radiotherapy, following localized recurrence of their disease. We analysed the @entity1 and treatment characteristics to determine the median overall survival as the primary end point. @entity344 was examined to determine if increased @entity137 occurred when the stomach was irradiated within the intrathoracic radiotherapy field. The median overall survival for @entity1 treated with curative intent using salvage definitive chemo-radiotherapy was 16 months and the 2-year overall survival is 21%. One @entity1 is in clinical remission more than 5 years after therapy. Age <60 years old and nodal recurrence were favourable prognostic factors. Treatment compliance was 93% with only one @entity1 unable to complete the intended schedule. Fourteen per cent of @entity1 experienced grade 3 or 4 @entity344 . Salvage definitive chemo-radiotherapy should be considered for good performance status @entity1 with @entity189 who have a locoregional relapse after primary surgery. The schedule is tolerable with low @entity137 and an acceptable median survival.

Salvage definitive chemo-radiotherapy for locally recurrent XXXX after primary surgery: retrospective review.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma', 'oesophageal carcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity', 'Gastrointestinal toxicity']
@entity189 :: (MESH:D002277,Disease) :: ['oesophageal carcinoma']
